Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Equity Average (2020 - 2025)

Historic Equity Average for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $273.6 million.

  • Mirum Pharmaceuticals' Equity Average rose 1869.63% to $273.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.6 million, marking a year-over-year increase of 1869.63%. This contributed to the annual value of $237.2 million for FY2024, which is 2139.79% up from last year.
  • Mirum Pharmaceuticals' Equity Average amounted to $273.6 million in Q3 2025, which was up 1869.63% from $244.2 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Equity Average's 5-year high stood at $273.6 million during Q3 2025, with a 5-year trough of $76.1 million in Q3 2021.
  • For the 5-year period, Mirum Pharmaceuticals' Equity Average averaged around $174.5 million, with its median value being $155.7 million (2022).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Equity Average crashed by 4068.03% in 2021, and later surged by 11095.33% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Equity Average (Quarter) stood at $88.3 million in 2021, then skyrocketed by 76.29% to $155.7 million in 2022, then surged by 66.3% to $258.9 million in 2023, then fell by 11.61% to $228.8 million in 2024, then rose by 19.56% to $273.6 million in 2025.
  • Its Equity Average was $273.6 million in Q3 2025, compared to $244.2 million in Q2 2025 and $229.4 million in Q1 2025.